<DOC>
	<DOCNO>NCT02471027</DOCNO>
	<brief_summary>This study registration study.The main research : curative effect neoadjuvant chemotherapy treatment ⅠB2 ⅡA2 locally advance cervical cancer.Research group : neoadjuvant chemotherapy combination cervical cancer radical hysterectomy.Control group : cervical cancer radical hysterectomy directly.Main observation index overall survival disease-free survival .</brief_summary>
	<brief_title>The Clinical Research Neoadjuvant Chemotherapy Combined Surgery Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>This study multicenter register study.Selected January 1 , 2009 June 31,2016 , accept neoadjuvant chemotherapy combine radical surgery radical surgery directly treatment , ⅠB2 ⅡA2 stage cervical cancer patient center participate research . Total number patient least 1000 cases.On January 1 , 2009 May 31 , 2015 , collect baseline data follow-up information hospitalize patient , call retrospective group.On June 1，2015 May 31，2016 , case group take prospective way collect baseline data ( call prospective group ) .Mainly collect follow-up information . 1.The main observation index : overall survival ( OS ) : time treatment first time ( first day neoadjuvant chemotherapy surgery ) calculation time death time last follow-up still alive ( four year ) . 2.Secondary outcome : 1 . 3 year disease-free survival ( DFS ) : operation time neoadjuvant chemotherapy time calculation first time recurrence/the time last follow-up time death . 2. quality life assessment : include EQ-5D health index scale FSFI scale . 3. economics index : direct indirect cost . 4 . High risk factor relapse analysis : lymph node positive rate , cervical local tumor change neoadjuvant chemotherapy , pathologic complete response rate neoadjuvant chemotherapy , tumor pathology classification , tumor stromal infiltration depth , Cut edge positive rate , Vascular infiltration clearance rate , etc . 5. perioperative : operation time , intraoperative blood loss , postoperative complication , postoperative mortality , infection , etc . 6. adverse reaction ( prospectie cohort study ) : application WHO anti-cancer drug adverse reaction degree RTOG/EORTC criterion evaluate different treatment adverse reaction . Subject supervision organization clinical research institute Peking University Clinical Research Institute .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 . Age great equal 18 2 . The initial treatment cervical cancer , Pathology squamous cell carcinoma , adenocarcinoma Adenosquamous carcinoma 3 . 2009 FIGO clinical staging IB2 , IIA2 stage cervical cancer 4 . Patients acceptted treatment neoadjuvant chemotherapy combine cervical cancer radical surgery cervical cancer radical surgery directly 5 . Inform consent form 1 . With severe complication tolerate surgery , chemotherapy 2 . Patients distant metastasis 3 . With uncontrolled seizure , central nervous system disease history mental disorder , researcher determine clinical severity affect clinical research 4 . The last five year history malignant diseases 5 . Have receive chemotherapy radiotherapy patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Locally advanced cervical cancer</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>Disease-free survival</keyword>
	<keyword>Overall survival</keyword>
</DOC>